Még nem toboroz
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
NCT07816978· 4. fázis· Sahlgrenska University Hospital· Forrás
Toboroz
The HIt HArd and hiT Early in Multiple Sclerosis Trial
NCT07517185· 2. fázis· Uppsala University· Forrás
Toboroz
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic
Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· 2. fázis· Janssen Cilag International· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
2025-524022-18-00· 2. fázis· Vaestra Goetalandsregionen· Forrás
Még nem toboroz
An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2024-519811-32-00· 4. fázis· Region Oestergoetland· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· 3. fázis· Vaestra Goetalandsregionen· Forrás
Toboroz
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· 3. fázis· Uppsala University· Forrás
Toboroz
Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX)
2023-508398-10-00· 4. fázis· Region Oestergoetland· Forrás
Fut, nem toboroz
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383· 4. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841· 3. fázis· AbbVie· Forrás
Toboroz
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
SACK
2022-501600-10-00· 3. fázis· Karolinska University Hospital· Forrás
Fut, nem toboroz
Ixekizumab Diabetes Intervention Trial (I-DIT)
NCT04589325· 2. fázis· Göteborg University· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
2024-518172-31-01· 3. fázis· Region Skane· Forrás
Fut, nem toboroz
Methotrexate in Patients with Early Rheumatoid Arthritis
NCT05353829· 4. fázis· Region Västerbotten· Forrás
Fut, nem toboroz
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416· 3. fázis· Pfizer· Forrás
Toboroz
Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan
NCT05132179· 3. fázis· Vastra Gotaland Region· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
NCT04910802· 4. fázis· Miriam Elfström· Forrás
Fut, nem toboroz
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318· 3. fázis· German CLL Study Group· Forrás
Toboroz
Does metformin reduce growth rate of small abdominal aortic aneurysms?
NCT04224051· 2. fázis· Uppsala University· Forrás
Fut, nem toboroz
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea to standard treatment against acute myeloid leukaemia (AML) is safe and efficacious
2023-509019-97-00· 1/2. fázis· Karolinska University Hospital· Forrás
Toboroz
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT03903835· 3. fázis· Karolinska Institutet· Forrás
Toboroz
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
NCT02901184· 3. fázis· Uppsala University· Forrás
Fut, nem toboroz
Adjuvant Low Dose Aspirin in Colorectal Cancer
NCT02647099· 3. fázis· Anna Martling· Forrás